

DISCLAIMER



Certain statements in this presentation constitute or may constitute forwardlooking statements. Any statement in this presentation that is not a statement of historical fact including, without limitation, those regarding the Company's future expectations, operations, financial performance, financial condition and business is or may be a forward-looking statement. Such forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected or implied forward-looking anv in statement. These risks and uncertainties include, among other factors, changing financial, economic, business, competitive or other market conditions. These and other factors could adversely affect the outcome and financial effects of the plans and events described in this presentation. As a result, you are cautioned not to place any reliance on such forward-looking statements. The forward-looking statements reflect knowledge and information available at the date of this presentation and the Company undertakes no obligation to update its view of such risks and uncertainties or to update the forwardlooking statements contained herein. Nothing in this presentation should be construed as a profit forecast or profit estimate and no statement in this presentation should be interpreted to mean that the future earnings per share of the Company for current or future financial years will necessarily match or exceed the historical or published earnings per share of the Company. This presentation has been prepared for, and

only for the members of the Company, as a body, and no other persons. The Company, its directors, employees, agents or advisers do not accept or assume responsibility to any other person to whom this presentation is shown or into whose hands it may come and any such responsibility or liability is expressly disclaimed. The material in this presentation is not provided for tobacco product advertising or promotional purposes. This material does not constitute and should not be construed as constituting an offer to sell, or a solicitation of an offer to buy, any products. The Company's tobacco products are sold only in compliance with the laws of the particular jurisdictions in which they are sold.

AN EXCITING FUTURE... A CLEAR PURPOSE


Something by the second second

for the world's smokers

......




OUR NGP JOURNEY - AN EXCEPTIONAL ASSET PORTFOLIO



*VON ERL vaping device 'my Von Erl' has been available in the US market since May 2016

DELIVERING A COMPELLING PROPOSITION LEVERAGING OUR COMPETENCIES





Delivering to smokers:

- / a satisfying, safer experience...
- / supported by innovation...
- / endorsed by a trusted brand...
- / underpinned by leading edge science...
- / and available wherever smokers go...

Delivering to shareholders:

- / additive revenues...
- / from a lean and scalable business...
- / light on assets...
- / high on returns...

DELIVERED STEP-UP IN FY18; ACCELERATING IN FY19



Product Portfolio




New Markets







- Built scalable execution model
- / 100k points of sale for myblu
- Growing rate of pods to devices
- / Expected annualised FY18 exit rate £0.3bn revenue



Level of Toxicants









Attractive Growth Category









13 Source: Smokers-World Health Organization 2015 for 107 markets; IHME 2012 data for remaining markets, Vapers- Internal estimate






Drivers of vaping for UK & US smokers








Main barriers for US & UK vape rejecters





Drivers of vaping adoption







Vaping Market Archetypes


Mainstream	Nascent	Less Developed	Not Permitted				
Vaping mainstream	Emerging category	Unfavourable conditions	Legal impediments				
and growing	with right conditions	(pricing, social pressure)	or banned				
9 markets	22 markets	54 markets	22 markets				
91m smokers	45m smokers	642m smokers	118m smokers				
21m vapers	4m vapers	10m vapers	1m vapers				
Example markets							

17 Source: Smokers - World Health Organization; Vapers - Internal model







Vaping Incidence Growth 2018 - 2025














Additive for Imperial








Significant economic incentive for smokers



Significant additive net revenue for Imperial







blu – Creating a Unique Brand

L.




blu – Creating a Unique Brand

L.





Top of mind and total unaided awareness among adult vapers











Portfolio to Deliver Smoker Satisfaction





Drivers for current vapers		UK & US smokers		Main barriers for vape rejecters		
76%	Harm reduction	Smokers	25%	Satisfaction	<mark>43%</mark>	
71%	Less expensive than cigarettes	who vape Smoker		Flavour	31%	
67%	More socially acceptable	Trier Rejecters	35%	Device confusion 22%		
		Smoker	40%	Public perception 249	%	
67%	Relaxing and enjoyment	Non-Triers		Vaping pricing 22%		










Simple Easy to use

Small and convenient 1 step click & go pod system



Taste & Satisfaction 16 great flavours 3 strengths Nicotine salts


Quality



Engineered by the trusted category pioneer



Vapour And Capacity Superior vapour production 1.5ml pods that last all day





Innovation Platform

Perfect for technological and range extensions




myblu INTENSE NICOTINE SALTS





WARNING: This product contains nicotine. Nicotine is an addictive chemical.

nicotine. Nicotine is an addictive chemical.





 Nicotine salts created by smokers for smokers


/ Great flavour

/ Silky smooth

/ Ultimate satisfaction


NICOTINE SALTS IMPROVE SATISFACTION AND CONVERSION













38 Sources: US at home test (4 pods of each pp) among smokers, June 2018. myblu w/nic salt vs. a leading pod system. Split no preference / Fontem Competitive Benchmark Test (June 2018)







39 Source: UK at home test. 2 days usage for each product among smokers and dualists. myblu w/nic salts vs. a leading HT brand.





41 SOURCE: USA IRI, UK Nielsen * Since rebranding of Von Erl product to myblu













/ Unique brand

/ Delivering smoker satisfaction

/ Clinically tested

/ Loved by smokers

/ Innovation platform





Innovation, Science

& the Environment

PIONEERING INNOVATION CAPABILITY



People



Roles



Great talent from leading FMCG companies



Industrial Design Mech. Eng. Electronics Eng. Embedded Software Physics Formulation Design Legal & Compliance

Capabilities



Category Insights

Rapid Prototyping


Performance Characterisation

Analytical Chemistry

Pilot Capabilities

Consumer Evaluation Intellectual Property





BEST IN CLASS PARTNERSHIPS



OPEN TO INSIGHTS, IDEAS, COLLABORATION, PARTNERSHIPS...




Deep internal capabilities connected to partner ecosystems win win



Partnership mind-set

Speed, precision and routine



Multiply impact

Multiply impact of own resources and capabilities



Navigating uncertainty

Navigate uncertainty and balance risks



New capabilities

Source new capabilities for growth

FOCUS ON BENEFIT PLATFORMS

Smoker Driven, Insight Leading





WE KNOW WHAT NEEDS SOLVING



FLAVOUR

Intensity Authenticity Fatigue Sensation Stimulation Trends Localisation Passive aroma Stability Visual perception Mouth feel DESIGN

Aesthetics Tactility Ergonomics Mobility Lip feel Customisable Identity & fit Trends Shelf presence

NICOTINE

Satisfaction Site of absorption Consistency Stability Tolerability Protonation Form Device compatibility Puffing topography CONVENIENCE & RELIABILITY

Ease of use Lifespan Power efficiency Consistency of experience Availability Shelf life Compatibility Maintenance & cleaning SAFETY

Emissions Toxicology Battery Materials Environmental impact Regulatory compliance Leak-free Child resistance COST

Affordability Value Materials Development Margin

Freedom to operate Ownable technology Patentability

IP

2018: A TRANSFORMATIVE YEAR FOR OUR PRODUCT PORTFOLIO







A revolution is happening



\$457bn 15+ billion

Estimated IOT market by 2020, with 40% in smart homes, wearables & connected health

Source: GrowthEnabler & MarketsandMarkets

Forecast number of connected (IOT) consumer devices worldwide by 2020

Source: Statista

69%

Of organisations have adopted or plan to adopt IOT in the next year

Source: State of IoT 2018, Cradlepoint Business Intelligence Report

Supercharging the experience












Quick and easy activation into ecosystem Empowering smokers with information







There at crucial moments







Next level safety & security

59 📐





Eliminating youth access by age verifying every smoker

60 📐

Rich data insights into how smokers use our products






Our connected bio



Flavour is key

Revolutionary flavour experience









Unique and impactful





Our unique hybrid offering for a true tobacco experience





An exciting new option for smokers










Small, handy perfect size for my handbag ,,





 $N \times$



Our heated tobacco offering Heated tobacco the way it should be









0 " T b

** The smoke is better than in all the other samples ,



Key pain points solved:





[•] Ease of cleaning








In-house capability





We've navigated a crowded IP space



150+ Patentable and unique innovations





PULZE



OUR ORAL NICOTINE PORTFOLIO





Nordic SoM **12%**


KNOX V Nordic SoM 9%





OUR ORAL NICOTINE PORTFOLIO





CATEGORY INNOVATORS

- Some Industry Firsts...
- / Strong & Super Strong
- / Dot led strength indicator now industry standard
- / Fresh mint & other flavours range

/ Slim pouches for improved mouth feel



NEW PRODUCT: SKRUF SUPER WHITE





/ Launched May 2018

/ Tobacco free

/ All white snus – rapidly growing
 segment


/ Clean, premium & modern design



building building

HARM REDUCTION SCIENCE


,0



Level of Toxicants


FRAMEWORK TO SUBSTANTIATE HARM REDUCTION POTENTIAL




















IN VITRO PRE-CLINICAL STUDIES PROVIDE A WEIGHT-OF-EVIDENCE APPROACH TO ASSESSING LONG-TERM HEALTH RISKS



2 years in to 5 year research toxicology program





93

IN VITRO PRE-CLINICAL STUDIES PROVIDE A WEIGHT-OF-EVIDENCE APPROACH




myblu did not elicit cell death, oxidative stress or inflammatory markers at 14 times the concentration used for cigarettes⁺



Severely damaged lung tissue after 27 cigarette puffs 27 puffs cigarette smoke



myblu did not elicit any biological response at 80 times the concentration used for cigarettes




* High content screening on human bronchial cells measuring cell stress and death




BIOMARKERS OF EXPOSURE FOR VAPERS INDISTINGUISHABLE FROM QUITTERS









www.imperialbrandsscience.com

Regulatory Toxicology and Planmarology 92 (2018) 226–238.	Regulatory Texicology and Pharmacology 87 (2017) 36–53 Contents lists available at ScienceDirect	TOXICOLOGY MECHANISMS AND METHODS, 2016 VOL. 26, NO. 6, 453-464 http://dx.doi.org/10.1080/15376516.2016.1196282
Contents jists avaluable at science/lifect Regulatory Toxicology and Pharmacology ELSEVIER journal homopage: www.elsevior.com/locate/yrtph	Regulatory Toxicology and Pharmacology	RESEARCH ARTICLE OPEN ACCESS Reductions in biomarkers of exposure (BoE) to harmful or potentially harmful constituents (HPHCs) following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers
Evaluation of the safety profile of an electronic vapour product used for two years by smokers in a real-life setting Tanvir Walele [®] , Jim Bush ^b , Annelize Koch ^c , Rebecca Savioz ^d , Claire Martin ^d , Grant O'Connell [®]	Measurement of cardiovascular and pulmonary function endpoints and other physiological effects following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers	Grant O'Connell ^a , Donald W. Graff ^b and Carl D. D'Ruiz ^c ⁹ Fontem Ventures, B.V. Scientific and Regulatory Affairs, Amsterdam, The Netherlands; ^b Celerion Inc, Lincoln, USA; ^c Fontem Ventures, B.V. Greensboro, NC, USA
 ⁴ Jenner Verhare, Korkbar Skonskan 101, 1001 IIA Annerdan, TAN Nebrolends ⁴ Cannos Chinin Rosanet Unit, Hydr Stran, Lenk, L52 9LH, UK ⁴ Cannos Chinin Rosanet, Martin 27(4), C144 900, UK ⁴ Cannos Astronomic Martin 27(4), C144 900, UK ⁴ Chronosis S.A., Arrdins 6, 1426 Concing, Switterland 	Carl D. D'Ruiz ^{a, *} , Grant O'Connell ^{b, **} , Donald W. Graff ^c , X. Sherwin Yan ^d ^a Clinical Study Consultant, Fourier Wentons, Groecothers, N.C. 193, ^b Feature Microsoft, M. USA, and Regulatory Affairs, Amsterdam, The Netherlands, ^c Oderion, Linicals, M. USA, ^d Antiliant Grance Concount (Manacher), M. 193, ^b Antiliant Grance Concount (Manacher), M. 193, ^c Antiliant Grance Co	ABSTRACT Changes in fifteen urine, blood and exhaled breath BoEs of HPHCs representing classes of compounds reported by FDA to be significant contributors to smoking-associated disease risks were measured in 105 clinical-confined subjects following candomization and a five dav force-dwitch from usual brand ArticLE HISTORY Received 25 April 2016 Revised 27 May 2016




VAPING IS NOT A GATEWAY TO SMOKING




/ Dynamic population modelling backed up by real data

/ Of 20,676 frequent US vapers...

- / Only 34 were never smokers that went on to smoke
- / Harm reduction potential to population as a whole



/ Dual users are on a longer journey to smoking abstinence



SUBSTANTIAL PRODUCT ASSESSMENT IS ESSENTIAL TO EVALUATE SAFETY AND HARM REDUCTION POTENTIAL





Product Characterisation

Pre-Clinical Studies

Clinical Studies

Pre-Market Consumer Studies

Post-Market Surveillance

The Environment

GROWING PUBLIC HEALTH ENDORSEMENT



The National Academies of SCIENCES ENGINEERING MEDICINE "complete switching from combustible tobacco cigarettes to e-cigarettes would be expected to reduce tobacco-related health risk"



"individuals should be encouraged to switch to the least harmful form of tobacco product possible; switching to the exclusive use of e-cigarettes is preferable to continuing to smoke combustible products"



"switching from tobacco cigarettes to vaping products will reduce a person's exposure to many toxic and cancer-causing chemicals"



"on the basis of current evidence vaping e-cigarettes is definitely less harmful than smoking cigarettes"



"vaping poses only a small fraction of the risks of smoking and switching completely from smoking to vaping conveys substantial health benefits"

SUPPORTIVE ENVIRONMENT FOR SMOKER CONVERSION KEY IN RAPIDLY EVOLVING SECTOR




Dynamic	Producer behaviours	Regulation & right

Dynamic environment experiencing exponential growth Producer behaviours inconsistent; no industry standard Regulation & right excise framework key to support smoker conversion

LEADERSHIP AND RESPONSIBILITY ARE KEY





FDA ACTION: POSITIVE STEP TOWARDS STRONGER CATEGORY






FDA News Release

FDA takes new steps to address epidemic of youth e-cigarette use, including a historic action against more than 1,300 retailers and 5 major manufacturers for their roles perpetuating youth access


- / Positive step to ensure compliance
- / Evolving robust and sustainable sector
- / Favours responsible operators
- / Fully support FDA actions & initiatives
- / Proactively implementing best practice
- / Preparing responses & proactive suggestions

STRONG CAPABILITIES AND A CLEAR AGENDA





Corporate Affairs resources on the ground in over 60 countries







Clear Market Focus



FMC pricing

108 Source: EVO market model, Millward Brown Global Tracker, WHO smoker data Note: Smoking population capped at 15m, FMC price capped at \$7



Smoker Adoption Model



OMNICHANNEL SMOKER ADOPTION MODEL

Building awareness, consideration and trust

Stimulating trial and purchase

BUY AGAIN

BELIEVE

BUY

Creating repeat purchase


BELONG

Fostering loyalty through community and belonging














Top of mind and total unaided awareness among adult vapers





Objective to grow from owning our brand to owning the category

/ Improved website
journeys on blu.com

Enhanced content strategy

Google

blu e cigarette blu pro kit blu cigs blue ice blu pro kit blu e cig blu e cig blu clearomizer


> vape pen uk vape starter kit ace of vapes vape juice vape liquid Vape liquid vape uk vape kits my first vape vape kits uk

Search engine traffic YoY **#1** rank blu key word search **#15** rank (up from #40) generic vape key word search

+96%























- Repurchase x2
- Conversion from **25 to 15** days

WARNING: This product contains nicotine. Nicotine is an addictive chemical. Always go full fruity Vape now

02018 Fortem NOT FOR SALE TO MINORS

4 x click through


Home banner click through +33%

Shop banner click through +22%





BRAND CONTENT CONSUMER CONTENT BELONG User-generated bluNation Consumer Social Channels Loyalty Program Content Service Brand Content Personalised **Refer a Friend** Sites CRM tribblereese • Follow Feddrar Device Soliton Store Locator Logie 🗂 Cannot Ponce City Market Register for myCARE™. tribblereese If you've been following my stories today, you got a feel for my though CARE enhance your myblu" vaporizer with process when putting together one of exclusive perks and benefits these mini masterpieces. It starts with an idea, a little direction & organization, and then the initiative to get off yo ass and I letter Metro to be a senter Actor alocalization conductor express yourself doing things you love. Thanks to the amazing @parispullen and the boys at Blu for following me around with a camera. Ps, in case you're wondering, the Blu? Shit's ###. OQI 28,716 views AUGUST 8 Personal Details Add a comment... .



119 Source: Crimson Hexagon; Brand 24 – Instagram only.

Posts tagged: @blucigsusa, @myblu, @blu_fr, @blu_Russia, @blunationuk, @blu_Deutschlandmedia mentions, @blu_vaping, #blulife, #blunation, #myblu, #blulanta, #blucigs, #blucig.

4Bs SMOKER ADOPTION MODEL

BELIEVE Building awareness, consideration and trust

Stimulating trial and purchase




BUY

Creating repeat purchase

BELONG Fostering loyalty through community and belonging





Building blu:


UK, Japan & USA





Building blu in the UK







The brand smokers and vapers aspire to in their search for something better



A leading brand and innovation pipeline




Market leading Sales and Marketing operation



New capabilities for new opportunities

building building









Retail















Retail 111 00 **£128m** Sales value **25%** Sales value





£229m Sales value

45% Sales value





£153m Sales value
30% Sales value







BUILDING MOMENTUM IN FY18



Building awareness through ATL, Brand Ambassadors and Social Media



Driving consideration and trial through impact at Point of Sale



Securing repeat purchase through omnipresence and tailored engagement



Welcoming consumers in our online community with bluNation



BUILDING BELIEF THROUGH AN INTEGRATED building CITY BY CITY CAMPAIGN





BUILDING BELIEF THROUGH AN INTEGRATED building **CITY BY CITY CAMPAIGN**



Building Awareness


Trial Through Device In Hand

Exploring Full Range












GROWING POS IMPACT WITH KEY PARTNERS







GROWING POS IMPACT WITH KEY PARTNERS




Impact at Point of Sale



Prioritising Relevant Distribution


*my*blu Distribution by Channel





STRONG ORGANIC SALES – DEMONSTRATING CONSUMER REACH









STRONG ORGANIC SALES – DEMONSTRATING REPEAT PURCHASE








136 Source: Aggregated EPOS for traditional retail





ACCELERATING INTO FY19



The brand smokers and vapers aspire to in their search for something better





Building blu in Japan





Relevant to Japanese Smokers



Strong Retail Partnerships



Extensive Activation







Relevant to Japanese Smokers

/ Addressing smoker needs

/ Menthol & fruit flavours



Strong Retail Partnerships

Extensive Activation

/ Convenience channel focus

/ Category captaincy



/ Widespread ATL media

/ Activation campaign










6% of the smoking population in Fukuoka bought *my*blu starter kit in the first 90 days



Building blu in the USA

building LARGEST VAPE MARKET... AND GROWING **Trend** 2018 Cigarette 36m **Smokers** / Strong growth Dualists 6.8m in vape (Tobacco & Vapour) / Driven by 21% YOY Vaper 3.3m accelerated Vape + Dualists smoker conversion Non-combustible 8.7m Tobacco **US** Nicotine 55m Consumers Consumers

145 Sources: E-cig intelligence; Fontem US Industry Forecast



BUILDING blu USA



Building a Lifestyle Brand



Since 2009 (US)



Maximising Availability







BRAND LIFESTYLE ACTIVATION MODEL



Building consideration: content generation and media coverage



Driving trial and consideration multi-platforms



Repeat purchase online: blu.com & e-tailers



Social media & influencers







Strengthening awareness to drive engagement



Media Partnerships





National Events









DRIVING PRODUCT TRIAL



Getting myblu into smokers hands

myblu Trial Promotions




Vape Engagement







8 cities - 72,000 smoker engagements








Creating a frictionless repurchase environment for blu users



myCare: Best Warranty Platform










User generated content and owned platform



Influencing smoker conversion

Social Media



>103% increase in followers


>80k unique visitors

Content Hub

Malibu VIP Tasting with Eddie Huang


Your bluprint to living the blu life


















STEP UP IN FY18; ACCELERATING IN FY19




Focus on best experience for smokers From a brand at the heart of everything we do

In a completely frictionless purchase environment












/Additive opportunity in a growing category

/ Clear levers to drive profitability


/ Delivering shareholder value






















Significant additive net revenue for Imperial

²⁴ Nased on net revenue per pod (1.5ml) versus pack of 20 FMC






/ Revenue per pod is higher than cigarettes

- / At a lower retail price
- / Additive revenue from converting smokers

24 L Based on net revenue per pod (1.5ml) versus pack of 20 FMC

/ Reflected in Feb 2018 LTIP

- / FY18 annualised exit rate of £0.3bn revenue
- / Significant revenue ambition







FY20 LTIP ambition

Man Marken and Marken a

£1.5bn net revenue

£1.70 - £2.00 avg. net revenue per pod

2-3 avg. pods per week (mix of dualists & soloists)

5-8m blu consumers

CLEAR LEVERS TO DRIVE PROFITABILITY




GROSS MARGIN ³		•		
Product innovation • Simplified manufacturing		c. 10	c. 100% increase	
Scale/increased a	utomation		c.70%	
c.35%				
Current GM %	Lower COGS	Net Revenue	Future GM %	

Opportunity

* GM analysis of myblu pods

CLEAR LEVERS TO DRIVE PROFITABILITY RAPIDLY SCALING MANUFACTURING CAPACITY





/ Outsourced manufacturing

/ Capital light model


/ Supports innovation

/ Scalable and agile

/ Capacities available to meet our ambitions


CLEAR LEVERS TO DRIVE PROFITABILITY





DELIVERING SHAREHOLDER VALUE BLU FINANCIAL DEVELOPMENT





Additive opportunity:

/ Significant revenue upside

/ Short term margin dilution

/ Accretive to EPS from FY19 exit

DELIVERING RETURNS




Delivering Sustainable Shareholder Returns

Significant Additive Growth




Scalable and Capital Light




Cash and Returns Focused





SOLVING FOR THE SMOKER SOLVING FOR SHAREHOLDER RETURNS







THANK YOU